Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Name: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
License: Public Domain

National Cancer Institute (NCI)

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

progressive glioblastoma, recurrent glioblastoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 148765
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.